Antengene scores $120 mln Series B
China-based Antengene Corporation, a clinical stage therapeutics company focused on oncology, has secured $120 million in Series B financing. Boyu Capital and FountainVest led the round with participation from Celgene Corporation, WuXi Corporate Venture Fund, Taikang, Qiming Venture Partners and TF Capital.
2 January 2019•1 min read
